Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Anlotinib.
- Who it may be relevant to
- Registry conditions: Craniopharyngiomas. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib. 2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
Detailed description
This study is a single-center, open-label, single-arm clinical trial designed to evaluate the safety and efficacy of anlotinib in the treatment of recurrent craniopharyngioma. Primary endpoints include progression-free survival (PFS), overall survival (OS), and objective remission rate (ORR), with assessment of treatment-related adverse events and quality of life.
Analysis Set:
Full Analysis Set (FAS): includes all patients who are randomized into the study, have received at least received at least one dose of study drug and have measurable baseline tumors.FAS will be used for efficacy FAS will be used for efficacy analysis. Per-Protocol Set (PPS): In the FAS, patients with at least one post-dose tumor imaging evaluation and a compliant tumor.
PPS: In the FAS, patients with at least one post-dose tumor imaging assessment, good compliance, and no significant violations or deviations from the trial protocol.
PPS will be used for secondary efficacy analysis. Safety Set (SS): Includes all patients who have received at least one dose of drug therapy and have completed at least one safety assessment.
SS will be used for safety analysis.
Sample size determination:
This is an experimental clinical study with the primary objective of assessing the safety and preliminary efficacy of the drug.
The sample size was designed to be relatively small due to resource constraints and the nature of experimental clinical studies. Based on the literature references and study design, we expected to enroll approximately 57 subjects.
Statistical analysis All statistical analyses will be performed using SAS 9.2 statistical analysis software. Separate independent efficacy and safety analyses will be performed, and no control will be established.
efficacy and safety analyses will be performed separately, with no control group and no between-group comparisons.ORR and DCR will be described using frequency and percentage, PFS and OS will be described using frequency and percentage.
ORR and DCR were described using frequency and percentage, PFS and OS were estimated by Kaplan-Meier method for survival, and All treatment-related adverse events were recorded and analyzed according to CTCAE 5.0 criteria.
Interventions
- Drug Anlotinib
Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).
Primary outcome measures
- Measurement of tumor volume on imaging (MRI) [Time frame: Through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Age 18-75 years old, regardless of gender
- recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data
- predominantly cystic or solid recurrence of the tumor
- measurable lesions (according to the RECIST criteria)
- Karnofsky score ≥ 70, expected survival ≥ 3 months
- laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control
- signed informed consent and willing to participate in the study
Exclusion criteria
- Have a combination of other intracranial tumors or severe brain lesions
- primary craniopharyngioma
- have severe uncontrolled heart, lung, kidney, or liver disease
- children, pregnant or breastfeeding women
- prior treatment with the same investigational drug
- active infections, including HIV, HBV, or HCV infections
- patients who do not meet the contraindications to the medication
- have a history of severe allergy to the investigational drug
- have psychiatric illnesses or cognitive impairments and unable to complete follow-up visits or understand the purpose of the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Southern Medical University, Nanfang Hospital, Department of Neurosurgery — Guangzhou
Identifiers
NCT: NCT06970145 · NFEC-2025-156